Mr Chew was previously an Executive Director at Goldman Sachs (Hong Kong and New York), responsible for the firm's proprietary investments, including growth capital, private equity and special situations. Other previous roles include Consultant Project Manager to Morgan Stanley and a number of positions at KPMG across the Asia-Pacific region, including Director at KPMG Consulting (Singapore and Sydney).
Mr Chew holds an MBA from the Wharton School (Palmer Scholar); an MA from the Lauder Institute, University of Pennsylvania; and a Bachelor of Information Systems from Monash University. Mr Chew is an Adjunct Professor at HKUST's MBA program and previously qualified as a chartered accountant.
Managing Director and Chief Executive Officer
His experience encompasses leadership, marketing, operations and project management across diverse therapeutic areas, including oncology, haematology, cell therapies, fertility and cardiovascular disease. Craig has worked at VivaZome Therapeutics, CSL, Serono UK, Bio Nova International, AVAX Australia and Cryptome Pharmaceuticals, in roles such as Executive Director, Chief Operating Officer, Sales and Marketing Director and Business Unit Manager. Prior to his appointment as MD, and CEO, Craig was the Chief Operating Officer at Invion from April 2018 to October 2019. Craig has a Science degree and post-graduate qualifications in Management and in Marketing.
Dr Campbell was previously the CFO and COO of ChemGenex Pharmaceuticals Ltd (ASX: CXS), where, as a member of the executive team, he helped transform a research-based company with a market capitalisation of $10 million to a company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA. In 2011, ChemGenex was sold to Cephalon for $230 million.
Dr Campbell currently sits on the Advisory Board of Deakin University’s Centre for Innovation in Mental and Physical Health and Clinical Treatment (IMPACT), along with other current roles that include Managing Director & CEO of Patrys Ltd (ASX: PAB) and Non-Executive Director of Prescient Therapeutics Ltd (ASX: PTX).
From 1999 to 2005, Mr Yamashita was President and CEO of Search Investment Group and founding CEO and CIO of Search Alternative Investment Ltd (SAIL), a major private global hedge fund and private equity investment practice headquartered in Asia.
Prior to Search Investments Group, Mr Yamashita was Managing Director and Head of Asia Capital Markets for Merrill Lynch from 1996 to 1998.
Mr Yamashita is currently Managing Partner at Polar Ventures and has held numerous positions as a 16-year veteran of Goldman Sachs and an advisor to various companies, including Plantation Timber Partners, Wuhan; Duty Free Shoppers, Asia; TVSN, Shanghai; and Mizuho Alternative Investments LLC.